February 24, 2014
The Federal Circuit on Monday upheld a Delaware district court's ruling that Banner Pharmacaps Inc., Mylan Pharmaceuticals Inc. and other generic-drug makers failed to prove that a patent owned by British pharmaceutical company GlaxoSmithKline LLC for the prostate reduction pill Avodart was invalid.